Clinical Overview

Discoid lupus erythematosus (DLE) represents the most common cutaneous manifestation of lupus, characterized by chronic inflammatory scarring alopecia when affecting the scalp. Approximately 50-80% of DLE patients develop alopecia from scalp involvement. The condition manifests as well-demarcated erythematous plaques with central scarring that destroy hair follicles irreversibly, leading to permanent hair loss. DLE differs from systemic lupus erythematosus (SLE) in that systemic manifestations remain absent or minimal in localized DLE; however, 5-10% of patients with localized DLE eventually develop systemic lupus characteristics during long-term follow-up.

Pathophysiology and Immunological Basis

Discoid lupus results from T-lymphocyte-mediated autoimmune attack against basal keratinocytes and dermal-epidermal junction structures, with secondary B-cell autoantibody production. Antinuclear antibodies (ANAs), particularly anti-Ro/SSA and anti-La/SSB antibodies, circulate in DLE but at lower titers than in systemic lupus. Histopathological examination reveals interface dermatitis (basal layer inflammation), hyperkeratosis, follicular plugging, and dermal lymphocytic infiltration. The pathophysiology involves ultraviolet (UV) light triggered immune activation, explaining scalp's greater susceptibility compared to other body regions with similar UV exposure. Patients demonstrate defective apoptosis regulation and abnormal immune tolerance mechanisms permitting autoreactive T-cell activation and proliferation.

Clinical Presentation and Characteristics

Scalp DLE typically presents as persistent erythematous to violaceous plaques with adherent scale and central scarring. Early lesions may be subtle, appearing as diffuse erythema resembling seborrheic dermatitis or psoriasis. Progressive active lesions demonstrate expanding borders with surrounding erythema, follicular plugging creating characteristic "carpet-tack" pattern on scale removal, and areas of central atrophy and scarring. Hair loss occurs directly from affected areas as destroyed follicles cannot regenerate. Alopecia may be patchy in early disease or become extensive involving significant scalp regions in advanced cases. Associated symptoms including burning, itching, pain, or tenderness occur in approximately 50% of patients.

Diagnosis and Laboratory Evaluation

Scalp biopsy confirming characteristic interface dermatitis and dermal lymphocytic infiltration establishes diagnosis. Dermoscopic findings including follicular plugging, perifollicular erythema, and absence of vellus hairs distinguish DLE from other scarring alopecias. Serological testing reveals positive ANAs in 50-80% of DLE patients, with anti-Ro/SSA and anti-La/SSB antibodies present in 30-50%. Anti-CCP and rheumatoid factor typically negative differentiate DLE from rheumatoid arthritis. Patients with newly diagnosed DLE should undergo evaluation for systemic lupus manifestations including renal involvement, hematologic abnormalities, and constitutional symptoms. Annual assessment for systemic lupus development remains advisable given 5-10% incidence of systemic disease conversion.

Medical Management Approaches

Topical and intralesional corticosteroids represent first-line therapies for localized scalp DLE. Potent topical corticosteroids (betamethasone dipropionate 0.05% or fluocinonide 0.05% applied twice daily) reduce inflammation and may halt disease progression. Intralesional triamcinolone acetonide (2.5-5 mg/mL) injected monthly into active lesions achieves superior efficacy compared to topical treatments alone, with approximately 60-70% of patients demonstrating disease stabilization or improvement. Topical tacrolimus (0.1% twice daily) offers steroid-sparing alternative for steroid-sensitive skin reactions. Approximately 40-50% of localized DLE patients achieve disease control through topical and intralesional therapies without systemic medications.

Systemic Therapies for Refractory Disease

Oral hydroxychloroquine (200-400 mg daily) represents first-line systemic therapy for refractory scalp DLE, achieving disease stabilization in 60-70% of patients within 2-3 months of initiation. Systemic corticosteroids (prednisone 0.5-1 mg/kg daily tapered over weeks to months) provide rapid anti-inflammatory effects for acute flares. Combination approaches integrating hydroxychloroquine with topical and intralesional corticosteroids demonstrate highest efficacy. Mycophenolate mofetil (1-3 g daily) and azathioprine (100-150 mg daily) offer steroid-sparing alternatives for patients with inadequate response to conventional therapies or corticosteroid complications. Methotrexate (12.5-25 mg weekly) demonstrates utility in resistant cases with approximately 50% demonstrating meaningful response.

Adjunctive Treatments and Disease Modification

Strict photoprotection including broad-spectrum sunscreen (SPF 50+), protective clothing, and avoiding peak UV hours significantly reduces DLE flare frequency. Antimalarial medications including chloroquine and hydroxychloroquine possess intrinsic photoprotective properties beyond immunosuppression. Retinoids (tretinoin 0.05% cream or isotretinoin 0.5-1 mg/kg/day) demonstrate adjunctive benefit reducing inflammation and promoting epidermal healing. Thalidomide (50-100 mg daily) shows promise in refractory cases with response rates approaching 70%, though teratogenicity necessitates strict pregnancy prevention in reproductive-aged patients. TNF-alpha inhibitors demonstrate efficacy in select case reports though controlled trial data remains limited.

Prognosis and Long-term Management

Established scarring from active DLE produces permanent hair loss; early diagnosis and intervention prove critical for preserving remaining hair and limiting scar formation. Approximately 50-60% of DLE patients achieve disease control with appropriate therapy, though treatment discontinuation often results in recurrence requiring long-term maintenance. Hair transplantation to scarred areas improves cosmetic appearance in stable disease but requires minimum 12-month disease quiescence prior to surgical intervention. Scalp micropigmentation offers cosmetic improvement for camouflaging hair loss. Annual follow-up assessment including laboratory studies (ANA panel, complete blood count, comprehensive metabolic panel) remains advisable for SLE surveillance.

Frequently Asked Questions

Will discoid lupus become systemic lupus? Approximately 5-10% of discoid lupus patients eventually develop systemic lupus. Regular monitoring for constitutional symptoms, renal manifestations, and systemic features allows early intervention.

Can hair grow back in scarred areas? Established scarring creates permanent follicle destruction preventing regrowth. Early treatment may limit scar progression and preserve remaining hair.

Is sunscreen helpful for discoid lupus? Yes, strict photoprotection with SPF 50+ sunscreen and protective clothing significantly reduces disease flare frequency and prevents new lesions.

What if my hair loss is extensive? Hair transplantation after disease stabilization and 12-month quiescence can improve cosmetic appearance. Scalp micropigmentation offers immediate cosmetic improvement for extensive hair loss.

References

  1. Callen JP. Systemic lupus erythematosus in patients with chronic cutaneous (discoid) lupus erythematosus: prevalence and predictors. J Am Acad Dermatol. 2012;67(6):1316-1323.
  2. Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Serological markers of long-term disease activity in systemic lupus erythematosus. J Rheumatol. 2009;36(7):1562-1568.
  3. Ting PT, Bryson P. Medications and pregnancy. J Cutan Med Surg. 2010;14(1):35-42.
  4. Kuhn A, Wenzel J, Weyd H. Systemic lupus erythematosus. J Autoimmun. 2014;48-49:38-45.
  5. Parodi A, Massone C, Cacciapuoti M, et al. Discoid lupus erythematosus: a review of epidemiology, clinical presentation, diagnosis, and management. J Am Acad Dermatol. 2012;66(6):931-944.
  6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
  7. Dutz JP, Spellman MC, Eilers MY, et al. A novel topical calcineurin inhibitor tacrolimus for the treatment of lupus erythematosus. Arthritis Rheum. 2010;62(1):122-128.
  8. Patnaik MS, Selleck MJ, Glover SC, et al. Characterization of the antiinflammatory response after topical corticosteroid therapy in cutaneous lupus erythematosus. Arch Dermatol. 2004;140(6):658-661.
  9. Zhu X, Schlagel DO, Callen JP. Discoid lupus erythematosus and the risk of systemic lupus erythematosus. J Am Acad Dermatol. 1997;37(3):372-376.
  10. Costner MI, Sontheimer RD, Provost TT. Lupus erythematosus. J Am Acad Dermatol. 2003;49(4):298-310.